Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer
Abstract:The incidence of penile cancer (PeCa) is increasing worldwide, however, the highest rates are reported in underdeveloped countries. The molecular mechanisms that underly the onset and progression of these tumors are still unclear. Therefore, our goal was to determine the genome-wide copy number alterations and the involvement of human papiloma virus (HPV) (TP53 and RB1), inflammatory (COX2 and EGFR), and PI3K/AKT pathway (AKT1, AKT2, EGFR, ERBB3, ERBB4, PIK3CA, and PTEN) associated genes in patients with PeCa … Show more
“…In PSCC, Busso-Lopes et al [ 10 ] found that copy number variations (CNVs) of 19 genomic regions are commonly detected in HPV + tumors, including in chromosomal regions 2q33.2-q33.3 and 2q35. Macedo et al [ 13 ] also found several loci, such as 2p12-p11.2, 14q32.33, and 2p16.3, presented CNV in most of HPV+ PSCCs, and several CNVs were correlated with clinicopathological factors. However, none of these results could directly indicate whether these differences between HPV-positive and HPV-negative PSCCs were induced by virus.…”
Section: Discussionmentioning
confidence: 99%
“…The integration pattern and characteristics of HPV in the PSCC genome are also unclear. Several studies have indicated that HPV-positive PSCC harbors a different genomic profile [ 10 , 11 , 12 , 13 ] and specific epigenetic alterations [ 12 ] when compared to HPV-negative PSCC or normal tissue. For instance, HPV-positive PSCC often harbors an APOBEC mutation [ 11 ]; copy number variations (CNVs) of 19 genomic regions are commonly detected in HPV-positive tumors [ 10 ]; HPV-positive tumors are characterized by the widespread loss of DNA methylation [ 12 ].…”
Human papillomavirus (HPV) is a significant etiologic driver of penile squamous cell carcinoma (PSCC). The integration pattern of HPV and its carcinogenic mechanism in PSCC remain largely unclear. We retrospectively reviewed 108 PSCC cases who received surgery between 2008 and 2017. Using high-throughput viral integration detection, we identified 35 HPV-integrated PSCCs. Unlike cervical cancer, the HPV E2 oncogene was not prone to involvement in integration. Eleven of the 35 (31.4%) HPV-integrated PSCCs harbored intact HPV E2; these tumors had lower HPV E6 and E7 expression and higher expression of p53 and pRb proteins than those with disrupted E2 did (p < 0.001 and p = 0.024). Integration breakpoints are preferentially distributed in or near host genes, including previously reported hotspots (KLF5, etc.) and newly identified hotspots (CADM2, etc.), which are mainly involved in oncogenic signaling pathways (MAPK, JAK/STAT, etc.). Regarding the phosphorylation levels of JNK, p38 was higher in HPV-positive tumors with MAPK-associated integration than those in HPV-positive tumors with other integration and those in HPV-negative tumors. In vitro, KLF5 knockdown inhibited proliferation and invasion of PSCC cells, while silencing CADM2 promoted migration and invasion. In conclusion, this study enhances our understanding of HPV-induced carcinogenesis in PSCC, which may not only rely on the E6/E7 oncogenes, but mat also affect the expression of critical genes and thus activate oncogenic pathways.
“…In PSCC, Busso-Lopes et al [ 10 ] found that copy number variations (CNVs) of 19 genomic regions are commonly detected in HPV + tumors, including in chromosomal regions 2q33.2-q33.3 and 2q35. Macedo et al [ 13 ] also found several loci, such as 2p12-p11.2, 14q32.33, and 2p16.3, presented CNV in most of HPV+ PSCCs, and several CNVs were correlated with clinicopathological factors. However, none of these results could directly indicate whether these differences between HPV-positive and HPV-negative PSCCs were induced by virus.…”
Section: Discussionmentioning
confidence: 99%
“…The integration pattern and characteristics of HPV in the PSCC genome are also unclear. Several studies have indicated that HPV-positive PSCC harbors a different genomic profile [ 10 , 11 , 12 , 13 ] and specific epigenetic alterations [ 12 ] when compared to HPV-negative PSCC or normal tissue. For instance, HPV-positive PSCC often harbors an APOBEC mutation [ 11 ]; copy number variations (CNVs) of 19 genomic regions are commonly detected in HPV-positive tumors [ 10 ]; HPV-positive tumors are characterized by the widespread loss of DNA methylation [ 12 ].…”
Human papillomavirus (HPV) is a significant etiologic driver of penile squamous cell carcinoma (PSCC). The integration pattern of HPV and its carcinogenic mechanism in PSCC remain largely unclear. We retrospectively reviewed 108 PSCC cases who received surgery between 2008 and 2017. Using high-throughput viral integration detection, we identified 35 HPV-integrated PSCCs. Unlike cervical cancer, the HPV E2 oncogene was not prone to involvement in integration. Eleven of the 35 (31.4%) HPV-integrated PSCCs harbored intact HPV E2; these tumors had lower HPV E6 and E7 expression and higher expression of p53 and pRb proteins than those with disrupted E2 did (p < 0.001 and p = 0.024). Integration breakpoints are preferentially distributed in or near host genes, including previously reported hotspots (KLF5, etc.) and newly identified hotspots (CADM2, etc.), which are mainly involved in oncogenic signaling pathways (MAPK, JAK/STAT, etc.). Regarding the phosphorylation levels of JNK, p38 was higher in HPV-positive tumors with MAPK-associated integration than those in HPV-positive tumors with other integration and those in HPV-negative tumors. In vitro, KLF5 knockdown inhibited proliferation and invasion of PSCC cells, while silencing CADM2 promoted migration and invasion. In conclusion, this study enhances our understanding of HPV-induced carcinogenesis in PSCC, which may not only rely on the E6/E7 oncogenes, but mat also affect the expression of critical genes and thus activate oncogenic pathways.
“…Studies have demonstrated that EGFR is often overexpressed its protein and gene dysregulation, has already been associated with advanced stage, lower overall survival and metastatic lymph node status (34). Downregulation of miR-145 may be one of the mechanisms for high expression of EGFR, especially in HPV positive tumors (35). Additionally, this microRNA can regulate pathways such as Wnt, TGF-beta, Calcium which are involved in cell growth, progression, survival, angiogenesis, and apoptosis (23).…”
Background: Human papillomavirus (HPV) infection is a risk factor for penile cancer (PC). The miR-145 expression has been correlated to this virus genomic amplification. In this context, this work aims to determine the expression level of miR-145 in penile tumors infected by high-risk HPV and correlate it with the clinicopathological characteristics of the tumor and protein expression of p53.Methods: Formalin-fixed paraffin-embedded from 52 patients with PC, at diagnosis and prior to any cancer treatment, were obtained. HPV identification was performed by nested type PCR, and miR-145 expression was obtained by qRT-PCR. Immunohistochemical analysis of p53 and Ki-67 was performed.Results: Tumoral miR-145 expression was significantly lower compared to adjacent tissue. Additionally, there was a significant reduction of miR-145 expression in invasion perineural, histological associated HPV, and absence of p53 expression in positive HPV cases. HPV infection was detected in 86.5%, the most frequent HPV16. Reduced disease-free survival was observed in patients with low expression of miR-145.Conclusions: Our data suggest that the underexpression of miR-145 may be triggered by HPV action, decreasing protein expression of p53, and being correlated with perineural invasion. Therefore, the deregulation of miR-145 provides clues as to the potential role in penile carcinogenesis and is also a potential candidate for validation in noninvasive samples.
“…Recently, Macedo et al performed array-CGH in 20 of 55 PeSCC (81.8% of them were HPV positive) (19). D e s p i t e o f n o t h a v i n g a n y s i g n i f i c a n t c l i n i c a lhistopathological association, a noteworthy number of altered chromosomal regions coincided with sites of HPV integration into the human genome.…”
Despite contemporary research efforts, the prognosis of penile squamous cell carcinoma (PeSCC) has not significantly improved over the past decade. Despite frequently encountered patient-related delayed medical consultations impairing outcomes, several other aspects contribute to the lack of advancement in the treatment of this condition. One essential reason is that translational research, a prerequisite for the clinically successful disease management, is still at an early stage in PeSCC as compared to many other malignancies.Preclinical experimental models are indispensable for the evaluation of tumor biology and identification of genomic alterations. However, since neither commercial PeSCC cell lines are available nor xenograft models sustainably established, such analyses are challenging in this field of research. In addition, systemic therapies are less effective and toxic without decisive breakthroughs over recent years. Current systemic management of PeSCC is based on protocols that have been investigated in small series of only up to 30 patients. Thus, there is an unmet medical need for new approaches necessitating research efforts to develop more efficacious systemic strategies. This review aims to highlight the current state of knowledge in the molecular alterations involved in the etiology and ensuing steps for cancer progression, existing preclinical models of translational research, clinically relevant systemic protocols, and ongoing clinical trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.